Esperion Therapeutics has retained The Chase Group, Inc. to secure an Executive Director, Project Management. This newly created key leadership position will elevate internal collaboration for the organization as it develops and commercializes first-in-class, oral, low-density lipoprotein cholesterol (LDL-C) lowering therapies for the treatment of patients with elevated LDL-C. Seasoned executives with CVOT project management leadership are encouraged to contact Bonnie Stofer for confidential consideration at bonnie@chasegroup.com.
Esperion Therapeutics Taps The Chase Group to Fill Newly Created Role
Esperion Therapeutics has retained The Chase Group, Inc. to secure an Executive Director, Project Management. This newly created key leadership position will elevate internal collaboration for the organization as it develops and commercializes first-in-class, oral, low-density lipoprotein cholesterol (LDL-C) lowering therapies for the treatment of patients with elevated LDL-C. Seasoned executives with CVOT project management leadership are encouraged to contact Bonnie Stofer for confidential consideration at bonnie@chasegroup.com.- Categories: Life Sciences, Pharmaceutical, Research & Development
The Chase Group Makes Another Successful Placement at Eli Lilly
The Chase Group is pleased to continue our partnership with Eli Lilly in the successful placement of a new Senior Medical Advisor, Medical Affairs on…
Aeglea BioTherapeutics Builds Rare Disease Clinical Development Team Through Partnership with The Chase Group, Inc.
Through our ongoing partnership, Aeglea Biotherapeutics has secured a Vice President, Clinical Development, Rare Disease. The new Vice President will play a crucial role in…-
Eli Lilly Welcomes New Vice President, Immuno-Oncology Global & US Medical Affairs
The Chase Group is pleased to announce the placement of the Vice President, Immuno-Oncology Global & US Medical Affairs for Eli Lilly. The successful candidate… 
The Chase Group Places VP of Clinical Development and Pharmacovigilance at Marinus Pharmaceuticals
The Chase Group is pleased to continue partnership with Marinus in building their leadership team with the recent placement of the Vice President of Clinical…-
The Chase Group Secures the Vice President, US and Global Medical Affairs for Eli Lilly
The Chase Group is pleased to announce the successful completion of the Vice President, US and Global Medical Affairs at Eli Lilly. The new Vice… 
Ionis Pharmaceuticals Secures Associate Director, Investor Relations
The Chase Group is pleased to announce our latest placement for Ionis Pharmaceuticals. Due to exciting organizational growth, Ionis welcomes a new Associate Director, Investor…